19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
15:24 , Aug 14, 2017 |  BC Extra  |  Preclinical News

Papers uncover predictive markers for BET inhibitor responses

A trio of papers published in Nature Medicine today challenge the notion that similar mutations in the same gene can predict the same drug responses across different types of cancer. While two separate teams of...
23:28 , Aug 3, 2017 |  BC Innovations  |  Tools & Techniques

Click bait

GlaxoSmithKline plc is developing click chemistry-based systems to pinpoint and quantify how drug candidates target DNA sequences, protein complexes and disease sites. The company believes the "click-probes" could slash failure rates in drug development by...
08:00 , Jan 5, 2015 |  BioCentury  |  Product Development

BETting early

Index Ventures-backed oncology play Oncoethix S.A. traded potentially larger returns for a faster clinical program for the company's primary asset when the Phase II program became too big for the small biotech to handle. On...
07:00 , Oct 30, 2014 |  BC Innovations  |  Cover Story

Redistributing BRD4 in inflammation

New clues to how inflammation leads to atherosclerosis from a group at Harvard Medical School point to a pivotal role for chromosomal redistribution of BRD4-a BET bromodomain protein involved in chromatin remodeling.1 The data provide...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Various BET bromodomain proteins In vitro studies suggest inhibiting distinct bromodomains within BET bromodomain-containing proteins could have...
08:00 , Nov 14, 2013 |  BC Innovations  |  Targets & Mechanisms

BETting on Th17 cells

Researchers at Constellation Pharmaceuticals Inc. have established a connection between BET bromodomain proteins and pathogenic T helper type 17 cells.1 The findings hint at therapeutic opportunities for this epigenetic target class in autoimmunity and inflammatory...